Stockscreener 앱 받기
36.50
4.41%
1.54
시간 외 거래:
36.53
0.03
+0.08%
전일 마감가:
$34.96
열려 있는:
$35.66
하루 거래량:
2.27M
Relative Volume:
1.08
시가총액:
$5.92B
수익:
-
순이익/손실:
$-328.94M
주가수익비율:
-14.91
EPS:
-2.4487
순현금흐름:
$-266.00M
1주 성능:
+6.20%
1개월 성능:
-8.68%
6개월 성능:
+174.64%
1년 성능:
+428.99%
1일 변동 폭
$35.66
$37.04
1주일 범위
$32.70
$37.04
52주 변동 폭
$3.72
$43.73
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
36.50 | 5.67B | 0 | -328.94M | -266.00M | -2.4487 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2025-11-10 | 업그레이드 | Stifel | Hold → Buy |
| 2025-11-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-10-16 | 개시 | Stifel | Hold |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - AOL.com
Aug Analyst Calls: Is Cogent Biosciences Inc forming a double bottomPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions - Yahoo Finance
Trading the Move, Not the Narrative: (COGT) Edition - Stock Traders Daily
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding - AOL.com
RTW Investments Increases Cogent Biosciences Stake to 2.7% of PortfolioNews and Statistics - IndexBox
Kynam Capital Sells $48M in Cogent Biosciences Shares | Q4 2025 Portfolio UpdateNews and Statistics - IndexBox
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - The Motley Fool
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - AOL.com
Biotech share surges 372% before being sold as latest selection climbs 40% in 2026 - Bitget
FDA accepts Cogent’s drug filing for treatment of rare blood disorder - MSN
Cogent Biosciences stock climbs after FDA accepts key drug application - MSN
HC Wainwright Analysts Lift Earnings Estimates for COGT - MarketBeat
Is Cogent Biosciences (COGT) one of the best multibagger stocks to buy according to billionaires? - MSN
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Ascendis Pharma (ASND) - The Globe and Mail
COGT Forecast, Price Target & Analyst Ratings | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
What Cogent Biosciences (COGT)'s FDA Acceptance of Bezuclastinib NDA Means For Shareholders - Yahoo Finance
COGT Shares Climb After FDA Accepts Bezuclastinib NDA for Non-Advanced SM - Bitget
Technical Analysis: What is the long term forecast for Cogent Biosciences Inc stockMarket Sentiment Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
COGT: Wedbush Reiterates Outperform Rating with $55 Price Target - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush - MarketBeat
Cinctive Capital Management LP Buys Shares of 111,058 Cogent Biosciences, Inc. $COGT - MarketBeat
Boothbay Fund Management LLC Cuts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Valuation In Focus After FDA Accepts Bezuclastinib NDA For Systemic Mastocytosis - simplywall.st
Raymond James Maintains Strong Buy for Cogent Biosciences (COGT) March 2026 - Meyka
Jefferies Initiates Buy Rating for Cogent Biosciences (COGT) wit - GuruFocus
Cogent Biosciences assumed with a Buy at Jefferies - TipRanks
Why Is Cogent Biosciences Stock Surging Monday?Cogent Biosciences (NASDAQ:COGT) - Benzinga
Cogent Biosciences (NASDAQ:COGT) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Shares Gap UpHere's Why - MarketBeat
Cogent Biosciences, Inc. shares surged 7.2% in pre-market trading after the U.S. Food and Drug Administration (FDA) officially accepted its new drug application for a rare disease treatment and will initiate the review process. - Bitget
Cogent Biosciences shares are trading higher ... - Benzinga
Cogent Biosciences (COGT) FDA Update on Bezuclastinib for NonAdv - GuruFocus
Cogent Biosciences Says FDA Accepted Marketing Application for Bezuclastinib in Non-Advanced Systemic Mastocytosis - marketscreener.com
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - The Manila Times
Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm) - TradingView
HighVista Strategies LLC Acquires 179,219 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. $COGT Shares Acquired by Fairmount Funds Management LLC - MarketBeat
Commodore Capital LP Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Boone Capital Management LLC Takes $13.57 Million Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires? - Insider Monkey
Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches - MarketBeat
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned - AOL.com
(COGT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cogent Biosciences (COGT) Valuation Check After New SUMMIT Trial Results For Bezuclastinib - Sahm
Will Cogent Biosciences Inc benefit from AI trends2025 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
JPMorgan raises Cogent Biosciences (COGT) PT to $67 on sector model update - MSN
Cogent Biosciences (COGT) advances bezuclastinib-sunitinib combination with breakthrough therapy designation (BTD) - MSN
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):